Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
JCO Precision Oncology|March 30, 2026
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA SubstudyYuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, et al.
International Journal of Clinical Oncology|May 20, 2023
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON studyAzusa Komori, Satoshi Otsu, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|January 23, 2021
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON studyTaiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Pancreas|August 4, 2021
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, et al.
Anticancer Research|March 28, 2023
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxelYasushi Ide, Taiga Otsuka, Mototsugu Shimokawa, et al.
Anticancer Research|July 7, 2021
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After ResectionHiroki Taguchi, Taiga Otsuka, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|March 6, 2026
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)Taro Shibuki, Riu Yamashita, Tadayoshi Hashimoto, et al.
Oncology|October 4, 2022
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON StudyJunichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, et al.
Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.
Scientific Reports|May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxelTsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.
Pageof 5